14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026
SNY vs TAK: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
SNY Overall Winner
6-Pillar Tally: SNY 5 – 0 TAK (1 Tie)
Matrix Metrics: SNY 7 – 3 TAK
As of Nov 16, 2026, Sanofi (SNY) is the stronger overall head-to-head candidate over Takeda Pharmaceutical Company Limited (TAK) in the Tradestie Institutional Equity Comparison Engine, winning 7–3 core matrix metrics and 5–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). SNY carries a Unified Composite Score of 31.7/100 (SELL) at $48.47 (8.9x Forward P/E, 22.3% operating margin), whereas TAK carries 48.0/100 (HOLD) at $21.61 (12.7x Forward P/E, 16.6% operating margin).
Composite vs. Pillar Nuance: While TAK currently prints a higher short-term Unified Composite Score (48.0/100 HOLD vs. SNY 31.7/100 SELL), SNY captures the overall institutional head-to-head verdict (7–3 matrix metrics and 5–0 across the 6 pillars) due to superior fundamental profitability (22.3% vs. 16.6% operating margin) and revenue trajectory (+15.7% vs. +6.7% YoY).
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on SNY vs TAK. Trailing 12-month operating profitability (SNY 22.3% vs TAK 16.6%) and valuation multiples (SNY 8.9x vs TAK 12.7x Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Drug Manufacturers - General value chain with $116.0B market capitalization and 22.3% operating margin.
OpEx & R&D Reinvestment52.0% of Rev ($15.6B)
90D Engineering Disclosures0 Published
TAK Moat ProfileScale & Operating Efficiency Moat
Drug Manufacturers - Specialty & Generic Operator
Competes within the Drug Manufacturers - Specialty & Generic value chain with $67.5B market capitalization and 16.6% operating margin.
OpEx & R&D Reinvestment48.2% of Rev ($12.4B)
90D Engineering Disclosures0 Published
Investor FAQ SNY vs TAK Key Questions & Quantitative Answers
As of Nov 16, 2026, Sanofi (SNY) is the stronger overall head-to-head candidate over Takeda Pharmaceutical Company Limited (TAK) in the Tradestie Institutional Equity Comparison Engine, winning 7–3 core matrix metrics and 5–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). SNY carries a Unified Composite Score of 31.7/100 (SELL) at $48.47 (8.9x Forward P/E, 22.3% operating margin), whereas TAK carries 48.0/100 (HOLD) at $21.61 (12.7x Forward P/E, 16.6% operating margin). Composite vs. Pillar Nuance: While TAK currently prints a higher short-term Unified Composite Score (48.0/100 HOLD vs. SNY 31.7/100 SELL), SNY captures the overall institutional head-to-head verdict (7–3 matrix metrics and 5–0 across the 6 pillars) due to superior fundamental profitability (22.3% vs. 16.6% operating margin) and revenue trajectory (+15.7% vs. +6.7% YoY).
SNY leads the Growth & Scale pillar: SNY posts +15.7% YoY revenue growth and +9.4% YoY earnings growth on $30.0B TTM revenue (74.3% gross margin, 22.3% operating margin), compared with TAK at +6.7% YoY revenue growth and -9.8% YoY earnings growth on $25.7B TTM revenue (64.8% gross margin, 16.6% operating margin). On trailing 12-month operating scale, SNY generates $30.0B in USD-normalized revenue versus $25.7B for TAK. In operating R&D and SG&A reinvestment, SNY deploys 52.0% of Rev ($15.6B) (0 90-day corporate R&D disclosures) versus 48.2% of Rev ($12.4B) (0 disclosures) for TAK.
SNY screens cheaper on headline valuation multiples. SNY trades at 8.9x Forward P/E, 24.1x Trailing P/E, 1.76x PEG, and 3.9x EV/Revenue (29.0% EBITDA margin), whereas TAK trades at 12.7x Forward P/E, N/M Trailing P/E, 0.47x PEG, and 2.6x EV/Revenue (29.1% EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against SNY (5.7% ROE) versus TAK (0.6% ROE) capital efficiency.
In options market volatility and institutional positioning, SNY carries 22.0% implied volatility (43rd %ile, Balanced (25th–60th %ile)), thin ADR options open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.20β · 27% Vol realized risk). By comparison, TAK carries 22.4% implied volatility (5th %ile, Compressed (<25th %ile)), thin ADR options open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (-0.02β · 22% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.